Document Detail


Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
MedLine Citation:
PMID:  23266894     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
After discontinuation of natalizumab (NAT), multiple sclerosis (MS) disease activity often recurs. We assessed the recurrence of clinical disease activity during the first year after switching from NAT to fingolimod (FTY) in patients with relapsing-remitting MS. The number of relapses and the annualized relapse rate (ARR) before, during and after NAT discontinuation were determined and compared between 26 MS patients who switched to FTY within 24 weeks, and 10 MS patients who remained without disease modifying therapy (therapy free group = TFG). Median follow-up post-NAT discontinuation was 55.1 weeks. In a subgroup (n = 20), the occurrence of contrast-enhancing-lesions (Gd+) on magnetic resonance imaging (MRI) was determined. Eleven patients (42 %) in the FTY group and seven patients (70 %) in the TFG had one or more relapses after cessation of NAT during follow-up (p < 0.05). One of the 11 (9 %) patients in the FTY group and 6/9 (67 %) patients in the TFG showed Gd+ lesions during follow-up (p < 0.05). Patients who switched to FTY ≤ 12 weeks after NAT discontinuation (n = 9) showed a trend for a lower post-NAT ARR compared to patients who started FTY therapy >12 weeks after NAT was stopped (n = 17). Most relapses in the FTY group occurred just before or within 8 weeks after starting FTY. Our observation suggests that initiation of FTY treatment after NAT discontinuation reduces the recurrence of disease activity compared to withdrawal without further immunomodulatory treatment. In the FTY group the ARR tended to depend on the time interval between discontinuation of NAT and initiation of FTY.
Authors:
Joachim Havla; Björn Tackenberg; Kerstin Hellwig; Ingrid Meinl; Markus Krumbholz; Florian Seitz; Christian Eienbröker; Ralf Gold; Reinhard Hohlfeld; Ingo Kleiter; Tania Kümpfel
Related Documents :
19761914 - Characteristics and corrective outcome of face asymmetry by orthognathic surgery.
8876484 - Resolution of mandibular arch crowding in growing patients with class i malocclusions t...
18405814 - Comparison of soft-tissue profiles after treatment with headgear or herbst appliance.
20133514 - Assessed facial normality after twin block therapy.
24486824 - Follow-up of 53 alzheimer patients with the moda (milan overall dementia assessment).
20573384 - A comparison of outcomes for interfascial and intrafascial nerve-sparing radical prosta...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-25
Journal Detail:
Title:  Journal of neurology     Volume:  -     ISSN:  1432-1459     ISO Abbreviation:  J. Neurol.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0423161     Medline TA:  J Neurol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Institute of Clinical Neuroimmunology, Medical Campus Grosshadern, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany, joachim.havla@med.lmu.de.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Supine to prolonged lateral position: a novel therapeutic maneuver for posterior canal benign paroxy...
Next Document:  Health expenditures, health outcomes and the role of good governance.